Wann machen die den Laden dicht? - 500 Beiträge pro Seite

[Dudde]

[Fliesel]

Gute Frage. Aber das Geld aus der Aktienausgabe dieses Jahres sollte doch wohl locker bis Ende 2003 reichen. Solange halten die m.E. sicher durch. Und falls dann bereits die ersten positiven Ergebnisse aus der Phasse III der Pemtumomab-Erforschung vorliegen, wer weiß ...

Mich würde viel mehr interessieren: Falls sich Pemtumomab 2004 wirklich als wirksam und vermarktbar herausstellen sollte - spült das genug Geld für die Ziterpartie um die anderen Entwicklungsprojekte in die Kasse? Von einem kometenhaften Anstieg des Kurses mal ganz zu schweigen. :-))

[Dudde]

Ich bin jedenfalls ein wenig investiert - wenns nicht klappt, isses auch egal - DEN Verlust kann ich auch noch verschmerzen

[Fliesel]

So seh ich`s auch. Mitte 2003 weiß man sicher schon mehr. Bis dahin ist ja Zeit, in ner schwachen Minute nachzukaufen.

[Dudde]

Wäre doch gelacht wenn ne Bombe platzt und ich wäre nicht dabei !!

Gruß vom Dudde

[merx]

auch das kann passieren:

Five UK biotech firms consider merger for cancer research

John Cassy
Tuesday August 13, 2002
The Guardian

A group of Britain`s biggest biotech companies have held tentative talks about combining to form a cancer company capable of competing with the biggest

ADVERTISEMENT

firms in the world.
The talks, involving cancer specialists Xenova, Antisoma, British Biotech and KS Biomedix, plus Oxford GlycoSciences, are understood to have the backing of Amvescap, a big institutional investor that holds shares in all of the firms.

Investors are pushing for the merger as a way to restore value to biotech stock prices after a period of decline.

However, consolidation in the British biotech sector has traditionally stumbled because of the competing aims and egos of the founder chairmen who typically control the groups.

Sealing a five way merger between the groups may prove too onerous a task even for some of the investment bankers who are pushing for the fee-generating deal to take place.

A source close to one of the companies said: "It`s a great idea in principle and one that has been knocking around the industry for 18 months but a deal is unlikely in the short-term."

Analysts have long argued that the fragmented biotech sector should consolidate into fewer, stronger groups. Biotech is a risky and expensive business with only one in 10 drugs entering clinical trials ever making it on to the market.

In volatile equity markets biotech firms are also finding it increasingly difficult to find new cash for research projects.

People close to the discussions say it is fear of a potential inability to raise new funds that could finally force the companies to seek strength through union.

The market value of British biotech firms has fallen dramatically over the past two years.

Together the five firms were worth £2.6bn in September 2000, yet today they are valued at just £280m.

Investment bank Nomura said it expected cash-rich Oxford GlycoSciences or British Biotech to be the main drivers of any deals, which would be all-share and give biotech more time to allow "undervalued assets to reach maturity".

The broker added: "Whoever runs the final entity is of less importance to the eventual outcome than that the projects survive to reach the market."


merx

[merx]

auch das kann passieren:

Five UK biotech firms consider merger for cancer research

John Cassy
Tuesday August 13, 2002
The Guardian

A group of Britain`s biggest biotech companies have held tentative talks about combining to form a cancer company capable of competing with the biggest

ADVERTISEMENT

firms in the world.
The talks, involving cancer specialists Xenova, Antisoma, British Biotech and KS Biomedix, plus Oxford GlycoSciences, are understood to have the backing of Amvescap, a big institutional investor that holds shares in all of the firms.

Investors are pushing for the merger as a way to restore value to biotech stock prices after a period of decline.

However, consolidation in the British biotech sector has traditionally stumbled because of the competing aims and egos of the founder chairmen who typically control the groups.

Sealing a five way merger between the groups may prove too onerous a task even for some of the investment bankers who are pushing for the fee-generating deal to take place.

A source close to one of the companies said: "It`s a great idea in principle and one that has been knocking around the industry for 18 months but a deal is unlikely in the short-term."

Analysts have long argued that the fragmented biotech sector should consolidate into fewer, stronger groups. Biotech is a risky and expensive business with only one in 10 drugs entering clinical trials ever making it on to the market.

In volatile equity markets biotech firms are also finding it increasingly difficult to find new cash for research projects.

People close to the discussions say it is fear of a potential inability to raise new funds that could finally force the companies to seek strength through union.

The market value of British biotech firms has fallen dramatically over the past two years.

Together the five firms were worth £2.6bn in September 2000, yet today they are valued at just £280m.

Investment bank Nomura said it expected cash-rich Oxford GlycoSciences or British Biotech to be the main drivers of any deals, which would be all-share and give biotech more time to allow "undervalued assets to reach maturity".

The broker added: "Whoever runs the final entity is of less importance to the eventual outcome than that the projects survive to reach the market."


merx